Dallas L. Thomas RAC MHA MPA Certified Lead Auditor

Dallas L. Thomas is a seasoned professional in the medical device and pharmaceutical industry with extensive experience in regulatory affairs, quality management systems, and FDA compliance. Here's a comprehensive overview of his background and expertise:

Professional Qualifications

Dallas L. Thomas holds several important credentials:

• Regulatory Affairs Certification (RAC) issued by the Regulatory Affairs Professionals Society4
• Master of Health Administration (MHA)
• Master of Public Administration (MPA)
• Certified Lead Auditor for ISO 13485:2016
• Six Sigma Yellow Belt (SSYB)4

Current Role and Expertise

Thomas currently serves as a Consultant for Pharmaceutical Drug, Medical Device, Science, IVD Manufacture, FDA 483, Regulatory, CGMP, and Audit at IQVIA.3 His areas of expertise include:

• FDA regulatory affairs
• Compliance
• Quality management systems
• Medical device industry regulations

Professional Experience

With 14 years of experience in the medical device industry, Dallas L. Thomas has developed a strong background in various aspects of regulatory affairs and quality management.2 He is known for his work in:

• Navigating FDA submission processes
• Approval procedures
• Post-marketing procedures for various dosage forms and therapeutic areas
• Addressing complex non-clinical and clinical issues

Additional Roles and Affiliations

Thomas is also associated with:

• Thomas Regulatory Resolutions (TRR), where he serves as a Medical Device Consultant1
• Pharmaceutical Development Group (PDG), where he contributes his expertise in regulatory affairs2

Language Skills

Dallas L. Thomas is multilingual, capable of communicating in:

• English
• Spanish (Hablo Español)
• Portuguese (Falo Português)1

Contact Information

For professional inquiries, Dallas can be reached at:

• Email: dallas@thomasregulatory.com
• Location: (Main Office) Florida, USA1

Dallas L. Thomas is well-regarded in the industry for his ability to assist FDA-regulated firms with regulatory strategies, emergency responses to FDA actions, and long-term product lifecycle management.2